NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected ...
Seeking Alpha

Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperforms

REZDIFFRA continues strong momentum, with Q1 2025 sales up 33% and positive EU regulatory progress, supporting my gradually bullish outlook. Madrigal's financials show an improving net loss and a ...
AOL

Is Madrigal Pharmaceuticals Stock a Buy?

Are we witnessing the rise of a new biotech leader? Madrigal Pharmaceuticals (NASDAQ: MDGL), a mid-cap company, might have as decent a shot at becoming as prominent in the field as most of its ...

DataM Intelligence 4 Market Research LLP: NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected to ...